(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/129142 A1

(51) International Patent Classification:
A61K 38/26 (2006.01) *A61P 1/00* (2006.01)

(21) International Application Number:
PCT/EP2021/085846

(22) International Filing Date:
15 December 2021 (15.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20214763.3 16 December 2020 (16.12.2020) EP
21166078.2 30 March 2021 (30.03.2021) EP

(71) Applicant: **ZEALAND PHARMA A/S** [DK/DK]; Sydmarken 11, 2860 Søborg (DK).

(72) Inventors: **SONNE, Kim**; Sydmarken 11, 2860 Søborg (DK). **AGERSNAP, Mikkel Askjær**; Sydmarken 11, 2860 Søborg (DK). **KNUDSEN, Kim Mark**; Sydmarken 11, 2860 Søborg (DK).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol, City of Bristol, BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/129142 A1

(54) Title: USE OF GLP-2 ANALOGUES IN PATIENTS WITH RENAL INSUFFICIENCY

(57) Abstract: The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.